×
About 24,705 results

ALLMedicine™ Hodgkin Lymphoma Center

Research & Reviews  7,519 results

The value of FDG PET/CT imaging in outcome prediction and response assessment of lympho...
https://doi.org/10.1007/s00259-022-05918-2
European Journal of Nuclear Medicine and Molecular Imaging; Kiamanesh Z, Ayati N et. al.

Aug 7th, 2022 - Treatment strategies of lymphoid malignancies have been revolutionized by immunotherapy. Because of the inherent property of Hodgkin lymphoma and some subtypes of non-Hodgkin lymphoma as a highly FDG-avid tumor, functional 18F-FDG PET/CT imaging i...

Acute Myeloid Leukaemia following Direct Acting Antiviral drugs in HCV-infected patient...
https://doi.org/10.1016/j.clinre.2022.102000
Clinics and Research in Hepatology and Gastroenterology; Carole S, Elena L et. al.

Aug 7th, 2022 - After several cases of peculiar hematological malignancies following introduction of new oral anti-hepatitis C virus (HCV) treatments in our recent practice, we aimed to systematically identify all cases of hematological malignancies (HM) in patie...

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hod...
https://clinicaltrials.gov/ct2/show/NCT02625480

Aug 5th, 2022 - The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL) or relapsed ...

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03907488

Aug 5th, 2022 - PRIMARY OBJECTIVE: I. To compare the progression-free survival (PFS) in patients with newly diagnosed advanced stage classical Hodgkin lymphoma randomized to N-AVD (nivolumab, doxorubicin hydrochloride [doxorubicin], vinblastine sulfate [vinblasti...

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03671018

Aug 5th, 2022 - This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of intravenous mosunetuzumab in combination with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL), and in participants with follicular ...

see more →

Guidelines  17 results

UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic La...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894347
British Journal of Haematology; Turton P, El-Sharkawi D et. al.

Nov 23rd, 2020 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast sy...

Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, A...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723685
Journal of Clinical Oncology : Official Journal of the Am... Mulder RL, Hudson MM et. al.

Oct 21st, 2020 - As new evidence is available, the International Late Effects of Childhood Cancer Guideline Harmonization Group has updated breast cancer surveillance recommendations for female survivors of childhood, adolescent, and young adult cancer. We used ev...

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Gu...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow...
https://doi.org/10.1093/annonc/mdy080
Annals of Oncology : Official Journal of the European Soc... Eichenauer DA, Aleman BMP et. al.

Oct 1st, 2018 - Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2018|Eichenauer DA,Aleman BMP,André M,Federico M,Hutchings M,|diagnosis,epidemiology,therapy,standards,

Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in ...
https://doi.org/10.6004/jnccn.2018.0066
Journal of the National Comprehensive Cancer Network : JN... Reid E, Suneja G et. al.

Aug 14th, 2018 - People living with HIV (PLWH) are diagnosed with cancer at an increased rate over the general population and generally have a higher mortality due to delayed diagnoses, advanced cancer stage, comorbidities, immunosuppression, and cancer treatment ...

see more →

Drugs  65 results see all →

Clinicaltrials.gov  866 results

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05169515

Aug 5th, 2022 - This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and CC-99282) in participants with B-cell NHL.

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03671018

Aug 5th, 2022 - This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of intravenous mosunetuzumab in combination with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL), and in participants with follicular ...

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
https://clinicaltrials.gov/ct2/show/NCT03755804

Aug 5th, 2022 - PRIMARY OBJECTIVES To evaluate the efficacy (adequate response) after 2 cycles of BEABOVP (bendamustine substitution for mechlorethamine in the original Stanford V chemotherapy backbone) in low-risk and intermediate-risk patients with classical Ho...

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
https://clinicaltrials.gov/ct2/show/NCT05371054

Aug 5th, 2022 - Background: High unmet medical need for relapsed/refractory non-Hodgkin lymphoma (NHL) after exhausting chemotherapy and/or chemo-immunotherapy regimens Targeted therapies aimed at disrupting cell death pathway in hematologic malignancies are emer...

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
https://clinicaltrials.gov/ct2/show/NCT05389423

Aug 5th, 2022 - Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV (PLWH) in the United States. Even in the modern era of antiretroviral therapy (ART), PLWH have an 11- to 17-fold higher risk of NHL than the general popu...

see more →

News  1,411 results

Firefighting a Carcinogenic Occupation, Warn Experts
https://www.medscape.com/viewarticle/977767

Jul 22nd, 2022 - Firefighting is a carcinogenic occupation that increases the risk of mesothelioma and bladder cancer, as well as potentially a host of other cancers, such as colon and prostate cancer, concludes an expert panel convened by the International Agency...

Nodular Sclerosing Hodgkin Lymphoma With Paraneoplastic Cerebellar Degeneration
https://www.mdedge.com/fedprac/article/256291/hematologic-malignancies/nodular-sclerosing-hodgkin-lymphoma-paraneoplastic
LCDR Denise Teh, DO, LT Hunter Culp, MD et. al.

Jul 15th, 2022 - Paraneoplastic syndrome is a rare disorder involving manifestations of immune dysregulation triggered by malignancy. The immune system develops antibodies to the malignancy, which can cause cross reactivation with various tissues in the body, resu.

A New First-line Regimen for Advanced Hodgkin Lymphoma?
https://www.medscape.com/viewarticle/975410

Jun 10th, 2022 - Patients with advanced classical Hodgkin lymphoma treated with first line brentuximab vedotin (Adcetris) plus chemotherapy showed substantial improvements in overall survival compared with those receiving standard chemotherapy, new research shows....

‘Exciting’ new gene therapy yields promising results
https://www.mdedge.com/hematology-oncology/article/255210/gene-therapy/exciting-new-gene-therapy-yields-promising-results
Heidi Splete

Jun 5th, 2022 - Patients with relapsed or refractory B cell non-Hodgkin lymphoma responded positively to a new therapy based on genome editing in early results from a phase 1 study, according to a news release from manufacturer Caribou Biosciences. In the first-i.

Ublituximab/Umbralisib BLA/sNDA in CLL and SLL Voluntarily Withdrawn
https://www.onclive.com/view/ublituximab-umbralisib-bla-snda-in-cll-and-sll-voluntarily-withdrawn

May 6th, 2022 - The pending biologics license application (BLA) and supplemental new drug application (sNDA) seeking the approval of the combination of ublituximab and umbralisib (Ukoniq; U2) in adult patients with chronic lymphocytic leukemia (CLL) and small lym...

see more →

Patient Education  4 results see all →